Search

everythinglearnresearchcommunity

for

Search:↓

Topical 2-deoxy-D-ribose (2dDR) regrows hair in mice almost as well as 2% Minoxidil. However, 2dDR may contribute to oxidative stress and hair loss due to the formation of advanced glycation end products (AGEs).

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.

RU58841 and Minoxidil can cause heart-related side effects like chest pain and heart racing. Pyrilutamide is suggested as a safer alternative, though it's new and costly.

The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.

The conversation discusses seeking a stronger treatment than Dutasteride (DUT) for hair loss. Suggestions include combining DUT with RU58841, increasing DUT dosage, and using transgender hormone replacement therapy or testosterone blockers, though some options may have feminizing side effects.

A user increased their RU58841 treatment from 5% to 8% to combat hair loss and is questioning the effectiveness of the higher dosage. Another user shared their extensive hair loss treatment regimen, suggesting that while 8% RU58841 might not significantly change results, it's worth trying as individual responses vary.

The user experienced hair regrowth using a combination of Minoxidil, Finasteride, and RU58841, with Minoxidil used initially and the other treatments added later. The user believes the combination of Finasteride and RU58841 contributed to the regrowth, with RU sourced from MVsupplement.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.

The conversation discusses the use of RU58841 for hair loss, with one user sharing a one-month difference in their hair after using it. Users discuss where to buy RU58841, potential side effects including heart issues, and mixed opinions on its effectiveness, with some questioning the need for treatment based on the before and after pictures.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

The conversation discusses using RU58841 mixed with topical minoxidil for hair loss, noting its chemical instability and storage challenges. A user shares their experience using RU58841 with ethanol and propylene glycol, mentioning no significant results yet.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

A user is considering an extensive hair loss treatment regimen including oral dutasteride, oral minoxidil, topical finasteride, tretinoin, microneedling, keto shampoo, laser comb, and PRP injections. Suggestions include simplifying the routine, possibly increasing minoxidil dosage, and considering alternatives like RU58841, while cautioning against using estrogen due to potential side effects.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.